Core Laboratories N.V. (CLB) Cash Flow Statement
Where CLB’s cash came from and went, 2025
December 31, 2025 · U.S. dollars- Cash from operations
- $37.0M −34.3% vs 2024
- Capital expenditures
- $14.7M 2.8% of revenue
- Free cash flow
- $22.3M 4.2% margin
- Returned to shareholders
- $14.3M 64% of free cash flow
- Change in cash
- $3.5M cash at year-end $22.7M
Drawn to scale: where the cash came from and how it was used. Hover for values.
CLB operating cash flow, capex and free cash flow
CLB cash flow trends, 2016–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | $131.9M2016 | $37.0M2025 | −13.2%/yr | |
| Capital expenditures | $11.7M2016 | $14.7M2025 | +2.6%/yr | |
| Free cash flow | $120.2M2016 | $22.3M2025 | −17.1%/yr | |
| Free cash flow margin | 20.2%2016 | 4.2%2025 | −16.0 pts | |
| Operating cash flow / net income | 2.072016 | 1.222025 | −0.85 | |
| Stock-based compensation | $22.1M2016 | $7.1M2025 | −11.8%/yr | |
| Dividends paid | $95.1M2016 | $1.9M2025 | −35.4%/yr | |
| Share buybacks (net) | $7.2M2016 | $12.4M2025 | +6.3%/yr | |
| Capex / revenue | 2.0%2016 | 2.8%2025 | +0.8 pts |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
CLB cash flow by activity
CLB net income vs operating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
CLB cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||
| Net income | $30.4M | $32.2M | $37.0M | $19.7M | $20.2M | −$96.9M | $93.7M | $79.8M | $83.1M | $63.9M |
| Depreciation & amortization | $14.6M | $15.0M | $15.8M | $17.2M | $18.5M | $20.9M | $22.6M | $23.1M | $24.5M | $26.9M |
| Stock-based compensation | $7.1M | $3.8M | $14.0M | $7.8M | $19.1M | $7.4M | $20.9M | $34.2M | $22.9M | $22.1M |
| Change in working capital | −$14.5M | $7.9M | −$28.8M | −$9.6M | −$11.5M | $35.1M | −$10.8M | −$9.9M | −$9.4M | $35.2M |
| Other non-cash items | −$616,000 | −$2.4M | −$13.2M | −$10.1M | −$9.7M | $91.5M | −$36.8M | −$15.4M | $3.1M | −$16.1M |
| Cash from operating activities | $37.0M | $56.4M | $24.8M | $25.0M | $36.6M | $57.9M | $89.5M | $111.8M | $124.3M | $131.9M |
| Investing activities | ||||||||||
| Capital expenditures | −$14.7M | −$13.0M | −$10.6M | −$10.2M | −$13.5M | −$11.9M | −$22.3M | −$21.7M | −$18.8M | −$11.7M |
| Investments (net) | — | −$6.4M | −$6.7M | −$3.9M | −$10.2M | $7.9M | −$5.7M | −$70.6M | −$20.6M | −$14.7M |
| Acquisitions & other investing | $12.5M | $13.0M | $10.6M | $10.2M | $13.5M | $11.9M | $22.3M | $21.7M | $18.8M | $11.7M |
| Cash from investing activities | −$2.2M | −$6.4M | −$6.7M | −$3.9M | −$10.2M | $7.9M | −$5.7M | −$70.6M | −$20.6M | −$14.7M |
| Financing activities | ||||||||||
| Dividends paid | −$1.9M | −$1.9M | −$1.9M | −$1.9M | −$1.8M | −$12.4M | −$97.6M | −$97.3M | −$97.1M | −$95.1M |
| Share repurchases & issuance (net) | −$12.4M | −$5.3M | −$2.2M | −$3.9M | −$8.3M | −$2.8M | −$3.3M | −$7.5M | −$16.9M | −$7.2M |
| Net borrowing (repayment) | −$15.0M | −$38.0M | −$9.0M | −$17.2M | −$71.0M | −$47.5M | $15.0M | $62.2M | $10.0M | −$217.2M |
| Shares issued | $0 | $0 | $0 | $0 | $60.0M | $0 | $0 | $0 | $0 | $0 |
| Other financing | −$2.0M | −$775,000 | −$5.4M | −$413,000 | −$1.4M | −$229,000 | $0 | −$10,000 | −$26,000 | $194.7M |
| Cash from financing activities | −$31.3M | −$46.0M | −$18.4M | −$23.4M | −$22.5M | −$63.0M | −$85.9M | −$42.5M | −$104.1M | −$124.9M |
| Summary | ||||||||||
| Net change in cash | $3.5M | $4.0M | −$308,000 | −$2.3M | $3.9M | $2.7M | −$2.0M | −$1.3M | −$364,000 | −$7.7M |
| Cash at end of period | $22.7M | $19.2M | $15.1M | $15.4M | $17.7M | $13.8M | $11.1M | $13.1M | $14.4M | $14.8M |
| Free cash flow | $22.3M | $43.4M | $14.2M | $14.7M | $23.0M | $46.0M | $67.3M | $90.1M | $105.5M | $120.2M |
| Free cash flow margin | 4.2% | 8.3% | 2.8% | 3.0% | 4.9% | 9.4% | 10.1% | 12.9% | 16.0% | 20.2% |
| Capex / revenue | 2.8% | 2.5% | 2.1% | 2.1% | 2.9% | 2.4% | 3.3% | 3.1% | 2.8% | 2.0% |
| Operating cash flow / net income | 1.22 | 1.75 | 0.67 | 1.27 | 1.81 | — | 0.96 | 1.40 | 1.50 | 2.07 |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | $5.8M | −$753,000 | $5.1M | $14.5M | $10.7M | $69,000 | $7.5M | $11.7M | $9.2M | $3.2M | $2.4M | $9.3M |
| Depreciation & amortization | $3.8M | $3.8M | $3.7M | $3.6M | $3.7M | $3.7M | $3.7M | $3.7M | $3.8M | $3.8M | $3.9M | $3.9M |
| Stock-based compensation | $902,000 | $5.0M | $1.1M | $1.3M | $538,000 | $4.2M | −$458,000 | −$1.9M | −$132,000 | $4.8M | $1.6M | $2.1M |
| Change in working capital | −$5.1M | −$778,000 | −$9.1M | −$4.9M | $2.0M | −$2.5M | $9.7M | −$915,000 | $8.5M | −$9.9M | $9.3M | −$14.1M |
| Other non-cash items | $2.3M | −$3.3M | $7.2M | −$6.1M | −$3.0M | $1.2M | $248,000 | $491,000 | −$4.2M | $3.5M | $2.2M | −$1.4M |
| Cash from operating activities | $7.8M | $4.0M | $7.9M | $8.5M | $13.9M | $6.7M | $20.6M | $13.1M | $17.1M | $5.5M | $19.4M | −$215,932 |
| Investing activities | ||||||||||||
| Capital expenditures | −$5.8M | −$4.9M | −$3.8M | −$3.0M | −$4.3M | −$3.6M | −$4.4M | −$2.7M | −$2.9M | −$3.1M | −$2.6M | −$3.5M |
| Investments (net) | — | — | — | $2.4M | −$1.6M | $772,000 | −$3.6M | −$491,000 | −$687,000 | −$1.7M | −$2.4M | −$3.4M |
| Acquisitions & other investing | $1.8M | $1.5M | $48,000 | $3.0M | $4.3M | $3.6M | $4.4M | $2.7M | $2.9M | $3.1M | $2.6M | $3.5M |
| Cash from investing activities | −$3.9M | −$3.4M | −$3.8M | $2.4M | −$1.6M | $772,000 | −$3.6M | −$491,000 | −$687,000 | −$1.7M | −$2.4M | −$3.4M |
| Financing activities | ||||||||||||
| Dividends paid | −$460,000 | −$460,000 | −$466,000 | −$465,000 | −$469,000 | −$469,000 | −$469,000 | −$469,000 | −$470,000 | −$468,000 | −$467,000 | −$469,720 |
| Share repurchases & issuance (net) | −$2.7M | −$4.0M | −$2.7M | −$5.0M | −$2.7M | −$2.0M | −$4.9M | −$196,000 | −$162,000 | −$44,000 | −$1.8M | −$218,000 |
| Net borrowing (repayment) | −$625,000 | $4.0M | −$4.0M | −$9.0M | $0 | −$2.0M | −$14.0M | −$8.0M | — | — | — | −$4.0M |
| Shares issued | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other financing | −$186,000 | $0 | $1,000 | −$2.0M | $10,000 | $9,000 | $0 | −$162,000 | −$13.0M | −$3.6M | −$16.2M | −$1.3M |
| Cash from financing activities | −$4.0M | −$457,000 | −$7.1M | −$16.5M | −$3.2M | −$4.5M | −$19.4M | −$8.8M | −$13.7M | −$4.1M | −$18.5M | −$6.0M |
| Summary | ||||||||||||
| Net change in cash | −$84,000 | $117,000 | −$2.9M | −$5.6M | $9.1M | $3.0M | −$2.3M | $3.8M | $2.8M | −$207,000 | −$1.5M | −$9.6M |
| Cash at end of period | $22.7M | $22.8M | $22.7M | $25.6M | $31.2M | $22.1M | $19.2M | $21.5M | $17.7M | $14.9M | $15.1M | $16.6M |
| Free cash flow | $2.0M | −$926,000 | $4.1M | $5.5M | $9.6M | $3.1M | $16.2M | $10.4M | $14.3M | $2.5M | $16.9M | −$3.7M |
| Free cash flow margin | 1.6% | −0.8% | 3.0% | 4.1% | 7.4% | 2.5% | 12.6% | 7.7% | 10.9% | 1.9% | 13.1% | −2.9% |
| Capex / revenue | 4.6% | 4.0% | 2.7% | 2.3% | 3.3% | 2.9% | 3.4% | 2.0% | 2.2% | 2.4% | 2.0% | 2.8% |
| Operating cash flow / net income | 1.35 | — | 1.55 | 0.59 | 1.30 | 96.52 | 2.76 | 1.12 | 1.87 | 1.72 | 7.98 | −0.02 |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
CLB cash generation
In fiscal 2025 (ended December 31, 2025), Core Laboratories generated $37.0 million of cash from operations (down 34.3%) and spent $14.7 million on capital expenditures, leaving free cash flow of $22.3 million, 4.2% of revenue. It returned $14.3 million to shareholders through dividends ($1.9 million) and net share buybacks ($12.4 million). Cash and equivalents rose by $3.5 million over the year.
Related: CLB income statement, CLB balance sheet, CLB dividend history. See the CLB stock overview for the latest quote and news.
CLB cash flow FAQ
What is Core Laboratories's free cash flow?
Core Laboratories's free cash flow was $22.3 million in fiscal 2025: $37.0 million of operating cash flow minus $14.7 million of capital expenditures It was $43.4 million a year earlier..
How much cash does Core Laboratories generate from operations?
Core Laboratories generated $37.0 million of cash from operating activities in fiscal 2025, 1.22 times its net income of $30.4 million.
How much does Core Laboratories spend on capital expenditures?
Core Laboratories spent $14.7 million on capital expenditures in fiscal 2025, 2.8% of revenue, compared with $13.0 million the year before.
How much stock does Core Laboratories buy back?
Core Laboratories spent $12.4 million on net share repurchases in fiscal 2025.
How much does Core Laboratories pay in dividends?
Core Laboratories paid $1.9 million in dividends in fiscal 2025, 8.4% of free cash flow.